Fulgent Genetics to Announce Fourth Quarter and Full Year 2019 Financial Results on Tuesday March 10, 2020

TEMPLE CITY, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its fourth quarter and full year 2019 financial results after the market closes on Tuesday March 10, 2020. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Vice President of Commercial Operations Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 9135649. An audio replay will be available in the Investors section of the company’s website or by calling (855) 859-2056 using passcode 9135649 through March 17, 2020.

About Fulgent Genetics

Fulgent Genetics is a technology company with a focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.

Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633, [email protected]